Non-nucleoside inhibitors of HCV polymerase NS5B. Part 2: Synthesis and structure-activity relationships of benzothiazine-substituted quinolinediones
de Vicente, J., Hendricks, R.T., Smith, D.B., Fell, J.B., Fischer, J., Spencer, S.R., Stengel, P.J., Mohr, P., Robinson, J.E., Blake, J.F., Hilgenkamp, R.K., Yee, C., Adjabeng, G., Elworthy, T.R., Tracy, J., Chin, E., Li, J., Wang, B., Bamberg, J.T., Stephenson, R., Oshiro, C., Harris, S.F., Ghate, M., Leveque, V., Najera, I., Le Pogam, S., Rajyaguru, S., Ao-Ieong, G., Alexandrova, L., Larrabee, S., Brandl, M., Briggs, A., Sukhtankar, S., Farrell, R., Xu, B.(2009) Bioorg Med Chem Lett 19: 3642-3646
- PubMed: 19457662
- DOI: https://doi.org/10.1016/j.bmcl.2009.05.004
- Primary Citation of Related Structures:
3G86 - PubMed Abstract:
A new series of benzothiazine-substituted quinolinediones were evaluated as inhibitors of HCV polymerase NS5B. SAR studies on this series revealed a methyl sulfonamide group as a high affinity feature. Analogues with this group showed submicromolar potencies in the HCV cell based replicon assay. Pharmacokinetic and toxicology studies were also performed on a selected compound (34) to evaluate in vivo properties of this new class of inhibitors of HCV NS5B polymerase.
Organizational Affiliation:
Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, CA 94304, USA. javier.devicente@roche.com